Withdrawal of Registration Statement (rw)
01 Octubre 2014 - 3:48PM
Edgar (US Regulatory)
Pure Bioscience, Inc.
1725 Gillespie Way
El
Cajon, CA 92020
October 1, 2014
VIA EDGAR
TRANSMISSION
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549-6010
Attention: Pamela Long, Assistant
Director
Re: Pure Bioscience, Inc.
Withdrawal of
Registration Statement on Form S-1
File No. 333-186394
Ladies and Gentlemen:
On behalf of Pure Bioscience, Inc., a
Delaware corporation (the Company), we hereby request, pursuant to Rule 477 of the Securities Act of 1933, as amended (the Securities Act), that the registration statement on Form S-1, together with all exhibits
and amendments thereto (File No. 333-186394), as initially filed with the Securities and Exchange Commission (the Commission) on February 1, 2013 (the Registration Statement) be withdrawn effective
immediately. We are seeking withdrawal of the Registration Statement because the Company has decided not to proceed with a registered offering at this time. The Registration Statement has not been declared effective and none of the Companys
securities have been sold pursuant to the Registration Statement.
Accordingly, the Company requests that the Commission issue an order granting the
withdrawal of the Registration Statement (Order) effective as of the date hereof or at the earliest practicable date hereafter. The Company also requests, in accordance with Rule 457(p) promulgated under the Securities Act, that
all fees paid to the Commission in connection with the filing of the Registration Statement be credited for future use for the Companys account.
Please provide a copy of the Order to Jeff Thacker, Esq. of DLA Piper LLP (US), via email at jeff.thacker@dlapiper.com or via facsimile at
(858) 638-5128. Should you have any questions regarding this request for withdrawal, please contact Jeff Thacker of DLA Piper LLP (US) by telephone at (858) 638-6728.
|
|
|
Very truly yours, |
|
Pure Bioscience, Inc. |
|
|
By: |
|
/s/ Peter C. Wulff |
|
|
Peter C. Wulff Chief Financial Officer and
Chief Operating Officer |
cc: Jeff Thacker, DLA Piper LLP (US)
PURE Bioscience (PK) (USOTC:PURE)
Gráfica de Acción Histórica
De May 2024 a Jun 2024
PURE Bioscience (PK) (USOTC:PURE)
Gráfica de Acción Histórica
De Jun 2023 a Jun 2024
Real-Time news about PURE Bioscience Inc (PK) (OTCMarkets): 0 recent articles
Más de Pure Bioscience, Inc. Artículos de Noticias